1511 GMT - Novo Nordisk first-quarter earnings could miss expectations on lower-than-expected prescriptions of Ozempic and Wegovy as well as some price declines, Bank of America Securities analysts write. Growth will also be hit by tough comparables, currency impacts and possibly higher costs, the bank says. "We expect sales guide to be lowered from 16-24% at constant exchange rates to 14%-22%, with our forecasts at the bottom of the new range." BofA assumes limited Ozempic/Wegovy inflection in the second quarter, while a key unknown is if whether a second-half inflection in prescriptions happens against tougher comparables. The bank lowers its price objective to 910 Danish kroner from 1,075 kroner and keeps a buy rating. Shares trade at 475.00 kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 28, 2025 11:11 ET (15:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.